Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jelissa Katharina Peter"'
Autor:
Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, Fabrice Helfenstein, Tim Roloff, Rahel Tarnutzer, Kerstin Grosheintz, Moritz Back, Carla Schaubhut, Sabina Wagner, Helena M. B. Seth-Smith, Patrick Scotton, Maurice Redondo, Christiane Beckmann, Tanja Stadler, Andrea Salzmann, Henriette Kurth, Karoline Leuzinger, Stefano Bassetti, Roland Bingisser, Martin Siegemund, Maja Weisser, Manuel Battegay, Sarah Tschudin Sutter, Aitana Lebrand, Hans H. Hirsch, Simon Fuchs, Adrian Egli
Publikováno v:
Microorganisms, Vol 10, Iss 5, p 857 (2022)
(1) Background: Some COVID-19 vaccine recipients show breakthrough infection. It remains unknown, which factors contribute to risks and severe outcomes. Our aim was to identify risk factors for SCoV2 breakthrough infections in fully vaccinated indivi
Externí odkaz:
https://doaj.org/article/9b13e0fcc1e64f10b1dcf474b4592430
Publikováno v:
Dermatologic Therapy. 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe378654d20c39129c6c3008ae25327d
https://doi.org/10.1111/dth.15435
https://doi.org/10.1111/dth.15435
Autor:
Madlen Stange, Eva Wuerfel, Jelissa Katharina Peter, Helena Seth-Smith, Tim Roloff, Severin Gsponer, Alfredo Mari, Blanca Cabrera Gil, Aitana Lebrand, Fanny Wegner, Ulrich Heininger, Julia Bielicki, Sarah Tschudin Sutter, Tanja Stadler, Karoline Leuzinger, Hans H. Hirsch, Markus Ledergerber, Simon Fuchs, Adrian Egli
BackgroundThe risk of SARS-CoV-2 (SCoV2) infection in schools and student households is typically assessed using classical epidemiology whereby transmission is based on time of symptom onset and contact tracing data. Using such methodologies may be i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d10e3be2d9e6e3990dd39dd27a13991
https://doi.org/10.1101/2022.01.26.22269824
https://doi.org/10.1101/2022.01.26.22269824
Autor:
Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, Fabrice Helfenstein, Tim Roloff, Rahel Tarnutzer, Kerstin Grosheintz, Moritz Back, Carla Schaubhut, Sabina Wagner, Helena Seth-Smith, Patrick Scotton, Maurice Redondo, Christiane Beckmann, Tanja Stadler, Andrea Salzmann, Henriette Kurth, Karoline Leuzinger, Stefano Bassetti, Roland Binggisser, Martin Siegemund, Maja Weisser, Manuel Battegay, Sarah Tschudin Sutter, Aitana Lebrand, Hans H. Hirsch, Simon Fuchs, Adrian Egli
IntroductionCOVID-19 vaccines significantly reduce SARS-CoV-2 (SCoV2)-related hospitalization and mortality in randomized controlled clinical trials, as well as in real-world effectiveness against different circulating SCoV2-lineages. However, some v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::400890703ba606891a3d356a87a2bbf9
https://doi.org/10.1101/2021.12.23.21268324
https://doi.org/10.1101/2021.12.23.21268324